Bristol-Myers Squibb Co.

NYSE:BMY   3:59:57 PM EDT
66.84
+0.37 (+0.56%)
4:00:00 PM EDT: $66.83 -0.01 (-0.02%)
Regulatory, Earnings Announcements

Bristol Myers Squibb Announces Positive Topline Results From Phase 3 Transform Trial Evaluating Breyanzi

Published: 06/10/2021 11:39 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol Myers Squibb Announces Positive Topline Results From Phase 3 Transform Trial Evaluating Breyanzi (lisocabtagene Maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed Or Refractory Large B-cell Lymphoma.
Bristol-myers Squibb Co - Study Met Primary and Key Secondary Endpoints, Demonstrating a Highly Statistically Significant Improvement in Event-free Survival.
Bristol-myers Squibb Co - Breyanzi Safety Results Consistent With Data From Pivotal Transcend Nhl 001 Trial.
Bristol-myers Squibb Co - Overall Survival Data Were Immature at Time of This Interim Analysis.
Revenue is expected to be $11.35 Billion
Adjusted EPS is expected to be $1.91

Next Quarter Revenue Guidance is expected to be $11.59 Billion
Next Quarter EPS Guidance is expected to be $1.96

More details on our Analysts Page.